Nov 30, 2021 / 07:15PM GMT
Maneka Mirchandaney - Evercore ISI Institutional Equities, Research Division - Analyst
Awesome. Hi, everyone. This is Maneka Mirchandaney from the Evercore ISI biotech team. Very pleased to be here with Incyte at a pretty important time for the company with what looks to be a pretty strong start for Opzelura.
From the team, we've got Christiana Stamoulis, who is EVP and CFO; Steven Stein, who is EVP and CMO; and Christine Chiou, who is the Head of IR. Thank you all for joining.
And I really wanted to start with Opzelura since that's clearly been the big area of focus this year. I think we're all kind of watching the IQVIA scripts that seems to be off to a good start for atopic derm. But maybe you can talk a little bit about the initial launch trajectory, how that's going, and some of the early feedback that you're hearing from physicians.
Questions and Answers:
Christiana Stamoulis - Incyte Corporation - Executive VP & CFOSure. So the launch is going very well. It's a very strong launch, and I'm sure people are looking at the IQVIA
Trustpilot
